SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

FDA Issues CRL for Summit Therapeutics’ Ivonescimab BLA

The FDA issued a Complete Response Letter for Summit Therapeutics’ biologics license application for ivonescimab plus platinum-containing chemotherapy in non-small cell lung cancer.

SMMT

Related stories